Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Dose Threshold Effect of Adenovirus-Mediated Factor VIII Gene Therapy in Hemophiliac Mice

1 Sept 2000

Abstract excerpt

While much is known about adenovirus biology from its development as a therapeutic gene delivery vehicle, an important question remains regarding the appropriate in vivo vector dose. We describe here an in vivo dose threshold effect with an adenoviral vector expressing human Factor VIII (FVIII) in hemophiliac mice. Upon administration of vector doses between 6 x 10(10) and 2 x 10(10) vector particles per mouse,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10985953
DOI: 10.1006/mthe.2000.0120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Dose Threshold Effect of Adenovirus-Mediated Factor VIII Gene Therapy in Hemophiliac MicePMID 10985953Read ↗

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia ASemantic proximity Read ↗

Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.Semantic proximity Read ↗

Transient costimulatory blockade overcomes immune barriers to durable and redosable liver-directed gene therapySemantic proximity Read ↗

A new adenoviral helper–dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivoSemantic proximity Read ↗

The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene TherapySemantic proximity Read ↗

Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII <i>in utero</i>Semantic proximity Read ↗

Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical ApplicationSemantic proximity Read ↗

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaquesSemantic proximity Read ↗

Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic MiceSemantic proximity Read ↗

Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral VectorSemantic proximity Read ↗

Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia ASemantic proximity Read ↗

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.